| Name | S63845 |
| Description | S63845 is a selective myeloid leukemia 1(MCL1) inhibitor that binds to human MCL1 with a Kd of 0.19 nM. |
| In vitro | METHODS: HCT-116 cells were treated with S63845 (0.001-10 μM), and the levels of MCL1 and BCL-XL proteins in the cells were analyzed by Western blot.
RESULTS S63845 effectively increased the level of MCL1 protein in the HCT-116 colon cancer cell line, but had no effect on the level of BCL-XL protein. The increase in MCL1 protein level was not accompanied by an increase in MCL1 mRNA level, but was associated with a prolonged protein half-life. [1] |
| In vivo | METHODS: S63845 (6.25, 12.5, 25 mg/kg, intravenous injection) was used to treat immunocompromised mice bearing human multiple myeloma (H929 and AMO1) xenografts, and its antitumor activity was observed.
RESULTS S63845 showed dose-dependent antitumor activity; the maximum tumor growth inhibition (TGImax) was 114% in the AMO1 model and 103% in the H929 model. [1] |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (2.41 mM), Sonication is recommended.
DMSO : 33.33 mg/mL (40.19 mM), Sonication is recommended.
|
| Keywords | S-63845 | S63845 | S 63845 | MCL-1 | Inhibitor | inhibit | Bcl-2 Family |
| Inhibitors Related | Cyanoacetamide | Ascorbyl palmitate | (S)-(+)-Ibuprofen | Pendimethalin | Amantadine | Hydralazine hydrochloride | Estradiol benzoate | Navitoclax | N-Hydroxyphthalimide | Venetoclax | Benzbromarone | Thymoquinone |
| Related Compound Libraries | Bioactive Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
